AGTR1 and Parkinson disease: AT1 activation intensifies the microglial inflammatory response, oxidative stress, and dopaminergic degeneration; moreover, AT1 receptor blockers have inhibitory effects on 6-hydroxydopamine and MPTP-induced PD models (Rey et al., 2007; Rodriguez-Pallares et al., 2008; Joglar et al., 2009).